NEW HAVEN, Conn., Feb. 8, 2010 (GLOBE NEWSWIRE) -- Achillion
Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and
development of treatments for the most challenging infectious diseases,
today announced that Michael D. Kishbauch, President and Chief
Executive Officer, will present a corporate and clinical update at the
12th Annual BIO CEO and Investor Conference at The Waldorf Astoria
hotel in New York City on Tuesday, February 9, 2010 at 3:30 p.m.
Eastern Standard Time.

Mr. Kishbauch's presentation will be webcast and accessible from the
News Center section of Achillion's website, www.achillion.com. To
ensure a timely connection to the webcast, it is recommended that users
register several minutes prior to the scheduled start time. An audio
archived version of the webcast will also be available for replay for
thirty days following the presentation date.

About Achillion

Achillion is an innovative pharmaceutical company dedicated to bringing
important new treatments to patients with infectious disease.
Achillion's proven discovery and development teams have advanced
multiple product candidates with novel mechanisms of action. Achillion
is focused on solutions for the most challenging problems in infectious
disease --hepatitis C, resistant bacterial infections and HIV. For more
information on Achillion Pharmaceuticals, please visit
www.achillion.com or call 1-203-624-7000.

ACHN-G


CONTACT:  Achillion Pharmaceuticals, Inc.
          Mary Kay Fenton
          (203) 624-7000
          mfenton@achillion.com

          Lippert/Heilshorn & Associates, Inc.
          Investors:
          Anne Marie Fields
            (212) 838-3777
            afields@lhai.com
          Bruce Voss
            (310) 691-7100
            bvoss@lhai.com